SCHEMBL357038

SCHEMBL357038

Cc1cnc(N2CCC(n3cc(F)c4c(Cl)ncnc43)CC2)nc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 6/20 0.38
SRC P12931 2/20 0.38
FLT3 P36888 2/20 0.38
PDGFRB P09619 1/20 0.38
KIT P10721 1/20 0.38
SIK1 P57059 1/20 0.38
RIPK4 P57078 1/20 0.38
DDR1 Q08345 1/20 0.38
RIPK1 Q13546 1/20 0.38
DSTYK Q6XUX3 1/20 0.38
RIPK3 Q9Y572 1/20 0.38
GPR119 Q8TDV5 4/20 0.34
ADK P55263 3/20 0.34
KCNH2 Q12809 2/20 0.33
MEN1 O00255 1/20 0.32
NR2F2 P24468 1/20 0.32
KMT2A Q03164 1/20 0.32
SCD O00767 1/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354783 0.91 RIPK2 (0.35) RIPK2SRCFLT3PDGFRBKIT
SCHEMBL358364 0.91 GPR119 (0.36) RIPK2SRCFLT3PDGFRBKIT
SCHEMBL356834 0.89 RIPK2 (0.32) RIPK2SRCFLT3PDGFRBKIT
SCHEMBL356951 0.88 RIPK2 (0.32) RIPK2SRCFLT3PDGFRBKIT
SCHEMBL354786 0.88 GPR119 (0.40) GPR119
SCHEMBL10140747 0.87 MALT1 (0.37) RIPK2SRCFLT3PDGFRBKIT
SCHEMBL355735 0.87 GPR119 (0.40) RIPK2GPR119
SCHEMBL356620 0.86 GPR119 (0.45) GPR119MEN1KMT2A
SCHEMBL356630 0.86 RIPK2 (0.40) RIPK2SRCFLT3PDGFRBKIT
SCHEMBL356843 0.84 GPR119 (0.32) RIPK2KITGPR119KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 RIPK2 2742/4885SRC 1364/4885FLT3 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.